Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company headquartered in Lewisville, Texas, with a focus on musculoskeletal care. The Orthofix news stream highlights developments across its spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including updates related to the 7D FLASH™ Navigation System.
Investors and healthcare professionals following Orthofix news can review regular earnings announcements, where the company reports net sales and segment performance for Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics. These releases often include commentary on trends in U.S. Spine Fixation, bone growth therapy performance, and the progress of its orthopedics business focused on limb reconstruction.
News coverage also features regulatory and product milestones, such as FDA 510(k) clearance and CE Mark for the TrueLok™ Elevate Transverse Bone Transport System and the global commercial launch of TrueLok Elevate. Orthofix uses these announcements to describe how TrueLok Elevate fits into its TrueLok family of multiplanar external fixators and supports limb preservation and diabetic wound-related treatment needs.
In addition, Orthofix issues releases about upcoming investor conference appearances and the timing of quarterly financial results and conference calls. For anyone tracking OFIX, this news page provides a centralized view of the company’s public communications on financial performance, product launches, regulatory clearances and investor events.
Orthofix Medical, a global medical device company, will be represented by CEO Jon Serbousek and CFO Doug Rice at two upcoming virtual investor conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021 at 3:30pm EST. The second is the Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 2:40pm EST. Live audio webcasts will be available on their website.
Orthofix Medical Inc. (NASDAQ:OFIX) will announce its third-quarter 2021 financial results on November 5, 2021, before the market opens. CEO Jon Serbousek and CFO Doug Rice will discuss the results in a conference call at 8:30 a.m. ET. Interested parties can join the call by dialing (833) 670-0709 (U.S.) or (343) 761-2533 (international) and referencing conference ID 1889020. A replay will be available for three weeks. Orthofix focuses on spine and orthopedic solutions and operates globally, distributing products in over 60 countries.
Orthofix Medical Inc. (NASDAQ: OFIX) reported a business update, noting challenges from increased deferred or rescheduled elective procedures due to COVID-19 restrictions. The company anticipates third-quarter 2021 revenue growth to align closely with a low single-digit increase compared to the same period in 2020. CEO Jon Serbousek expressed confidence in the company’s strategic initiatives and growth potential, particularly with products like the M6-C™ artificial cervical disc and the FITBONE™ limb lengthening system.
Orthofix Medical Inc. (NASDAQ:OFIX) has announced that over 60,000 M6-C artificial cervical discs have been implanted globally, establishing a strong market position. The M6-C disc, approved by the FDA in 2019, mimics the natural motion of a disc and serves as an alternative to cervical fusion. The company is also conducting a two-level Investigational Device Exemption study for the M6-C disc to compare its effectiveness against traditional treatments. Orthofix will showcase the M6-C disc at the upcoming North American Spine Society annual meeting in Boston.
Orthofix Medical Inc. (NASDAQ: OFIX) has appointed Wayne C. Burris to its Board of Directors and the Audit and Finance Committee. Burris, who served as Senior VP and CFO at Roche Diagnostics until July 2019, brings over 35 years of experience in finance, including strategic roles in various healthcare divisions. His expertise in U.S. and international accounting is expected to contribute positively as Orthofix continues its growth initiatives. The company's mission remains focused on delivering innovative solutions in spine and orthopedics.
Orthofix Medical Inc (NASDAQ:OFIX) has launched the Opus™ Mg Set, a synthetic magnesium-based osteoconductive scaffold designed for orthopedic procedures. This innovative product aids in filling non-structural bony voids, enhancing the natural bone-healing process. The Opus Mg Set is available in moldable and injectable forms, providing immediate compressive strength and significant bone remodeling, with preclinical studies indicating over 80% bone remodeling in 26 weeks. This launch reflects Orthofix’s commitment to advancing biologic solutions in orthopedic care.
Orthofix Medical Inc. (NASDAQ:OFIX) announced participation in the Sidoti Virtual Investor Conference on September 23, 2021, at 2:30 p.m. ET. President and CEO Jon Serbousek and CFO Doug Rice will engage in a fireside chat, with one-on-one meetings before and after the session. Interested parties can access the live webcast on the company’s website. Orthofix focuses on innovative medical solutions in spine and orthopedics, distributing products in over 60 countries. For more information, visit www.orthofix.com.
Orthofix Medical Inc. (NASDAQ:OFIX) announces the first U.S. pediatric patient implanted with the Fitbone intramedullary lengthening system. This FDA-cleared solution is designed for limb lengthening of the femur and tibia, available in sizes 9mm, 11mm, and 13mm. The Fitbone system is now compatible with the OrthoNext digital platform, enhancing preoperative planning. The system has been successfully used in over 3,500 cases globally, reflecting Orthofix's commitment to improving patient outcomes in orthopedic care.
Orthofix Medical Inc. (NASDAQ:OFIX) reported Q2 2021 financial results, with net sales of $121 million and EPS of $0.12. Adjusted EPS rose to $0.32, reflecting improved performance over pre-COVID levels. Key growth drivers include the M6-C cervical disc and FITBONE lengthening system. Gross profit increased to $94 million, with a gross margin of 77.4%. However, cash flow from operations fell to $0.3 million. The 2021 outlook anticipates net sales between $468 million and $474 million, representing a 15.1% to 16.6% increase.
Orthofix Medical Inc (NASDAQ:OFIX) announced the first patient implant in a pivotal FDA clinical study evaluating the M6-C™ artificial cervical disc for two-level cervical radiculopathy. This study will compare the disc's safety and effectiveness against anterior cervical discectomy and fusion (ACDF). A total of 263 patients will be enrolled, aiming for a primary endpoint of overall success at 24 months. The M6-C disc has been implanted over 55,000 times globally, reinforcing its position as a promising alternative to cervical fusion.